Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02338167

Praegnant Breast Cancer: Early/Advanced/Metastatic

Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only regard-ing therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge.

Recently, novel advances in breast cancer therapy aim at the targeted therapy of tumor entities and identification of patients, for whom the greatest therapy benefit, and the least side effects are expected.

However molecular assessment of the patient and the tumor in the metastatic situation is not performed on a routine basis and in many cases tumor character-istics from the primary tumor are considered reliable enough to make therapy decisions for the metastatic patients. Although molecular reassessment of tu-mor characteristics from tumor material of the metastasis is recommended in national guidelines, only a minority of patients is biopsied, because of the inva-siveness of the procedure, even though biopsy related complications are reported to be rare.

With modern analytic methods from blood based biomaterial there seems to be an opportunity to correlate blood based tumor assessments with actual charac-teristics of the tumor. These include expression analysis, tumor mutation analy-sis, tumor gene copy number aberrations and others. One of the main aims of the PRAEGNANT study is therefore to establish an infrastructure for the compre-hensive analysis of tumor and metastatic molecular characteristics of the patient and the tumor.

Furthermore, health care related outcomes as well as health economics provide novel approaches for integration of patients in study conduct and health care awareness and are study aims of the PRAEGNANT study.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Advanced/Metastatic Breast Cancer Breast Cancer (Early Breast Cancer) Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Klinikum Sindelfingen-Böblingen gGmbH, Böblingen, Baden-Wurttemberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for the early breast cancer setting:

  • Adult breast cancer patients (age ≥18 years)
  • Patients with breast cancer and no evidence of distant metastases with a diagnosis not longer than 91 days before study entry
  • Patients, who are able and willing to sign the informed consent form

Inclusion criteria

for the advanced/metastatic setting:

  • Adult women aged ≥18 years
  • Patients with the diagnosis of invasive breast cancer (in German: Mammakarzinom, as op-posed to "non-invasive"= ductales Carcinoma in situ; irrespective of status of BC, e.g. TNM, re-ceptor status etc.) and
  • Patients, who are willing and able to sign the informed consent form
  • Patients with metastatic or locally advanced, inoperable disease proven by clinical measures (i.e. standard imaging)

Exclusion criteria

  • Patients who did not sign the informed consent form
  • Patients, who are not eligible for observation due to non-availability and/or severe comor-bidities as evaluated by the treating physician

Treatment and study plan

blood sampling

Procedure

A blood sample will be taken during a routine blood draw

Primary outcomes

  1. MBC (Metastatic Breast Cancer): Discovery of biomarkers, which predict progression free survival (PFS)

    Time frame: PFS defined as the time to the first progression after study inclusion from the last time of progression before or at study entry

    Analyses will be done separately for each therapy line. Biomarkers include gene expression profiling of the primary tumor and the corresponding metastases, somatic mutations, germline genetic variation, epigenetic changes and miRNA variation up to a total of 500,000 biomarkers.

  2. EBC (Early Breast Cancer): Assessment of disease free sur-vival (DFS)

    Time frame: up to 60 months

    DFS defined as the time to the first disease recurrence after study inclusion from time of primary diagnosis before or at study entry

Secondary outcomes

  1. MBC: Assessment of overall survival (OS)

    Time frame: OS is defined as the time to death from the date of the last progression before or at study entry.

    OS is defined as the time to death from the date of the last progression before or at study entry.

  2. MBC: Assessment of breast cancer specific survival (BCSS)

    Time frame: Time to death from the date of the last progression before or at study entry.

    BCSS is defined as the time to to death due to breast cancer from the date of the last progression before or at study entry.

  3. MBC: Objective response

    Time frame: up to 60 months

    Objective response is defined as the best-documented response to the therapy started at study entry or the last therapy started before study entry.

  4. MBC: Description of therapies used in the metastatic setting

    Time frame: after 60 months (after study completion)

    Therapies will be categorized and descriptive statistics will be presented.

  5. MBC: Quality of life

    Time frame: Study entry and every 3 month or following a change of a therapy line(event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Assessed with EORTC QlQ-C30 and Visual Analog Scala

  6. MBC: Therapy adherence

    Time frame: up to 60 months

    Defined as the percentage of patients in which treat-ments which are terminated as per patients' wish or because of treatment related side effect.

  7. MBC: Influencing Factors of Depression in patients with metastatic breast cancer

    Time frame: Study entry and every 3 month or following a change of a therapy line (event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Depression will be assessed by patient reported questionnaires e.g. CESD-R.

  8. MBC: Incidence of adverse events, serious adverse events will be reported.

    Time frame: up to 60 months

    According to NCI Common Toxicity Criteria Version 4.03.

  9. MBC: Percentage of women, who will receive results of molecular tests undertaken in the context of the scientific objectives of this trial.

    Time frame: Once at end of study

    Number of patients who will receive molecular testing results compared to the total number of included patients.

  10. MBC: Feasibility and satisfaction regarding receipt of molecular testing results (including hereditary genetic alterations)

    Time frame: Once at end of study

    Assessed with a physician and patient questionnaire and documentation of possible confirmatory testing for changes in therapy or eligibility for interventional clinical trial screening.

  11. MBC: Health economics for women with metastatic and/or locally advanced, inoperable breast cancer.

    Time frame: Study entry and every 3 month or following a change of a therapy line (event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    EORTC QLQ C-30 (Version 3.0) (among others) and actu-al documented costs of diagnostic procedures, therapies, treatment of side effects and care for tumor-associated symptoms will be used to calculate health care costs, quality adjusted life years (QALY) and incremental cost effectiveness ratios (ICER) between patient groups.

  12. MBC: Patient reported influencing factors on therapy adherence in patients metastatic and/or locally advanced, inoperable breast cancer.

    Time frame: Study entry and every 3 month or following a change of a therapy line(event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Patient reported adherence for orally administered therapies will be assessed with suitable questionnaires.

  13. EBC: Assessment of distant disease-free survival (DDFS)

    Time frame: Up to 60 months

    DDFS defined as the time to the first distant disease recurrence after study inclusion from time of primary diagnosis before or at study entry.

  14. EBC: Quality of life

    Time frame: Study entry and every 3 month or following a change of a therapy line (event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Assessed with EORTC QLQ C-30 (Version 3.0), EORTC QLQ-BR23 and the EQ-Visual Analog Scale (VAS)

  15. EBC: Assessment of overall survival (OS)

    Time frame: OS is defined as the time to death from the date of the last progression before or at study entry.

    OS is defined as the time to death from the date of the primary diagnosis before or at study entry.

  16. EBC: Assessment of breast cancer specific survival (BCSS)

    Time frame: Time to death due to breast cancer from the date of the primary diagnosis before or at study entry.

    BCSS is defined as the time to death due to breast cancer from the date of the primary diagnosis before or at study entry.

  17. EBC: Description of therapies used in the early breast cancer setting

    Time frame: after 60 months (after study completion)

    Therapies will be categorized, and descriptive statistics will be presented.

  18. EBC: Percentage of women, who will receive results of molecular tests undertaken in the context of the scientific objectives of this trial.

    Time frame: Once at end of study

    Number of patients who will receive molecular testing results compared to the total number of included pa-tients.

  19. EBC: Feasibility and satisfaction regarding receipt of molecular testing results (including hereditary genetic alterations)

    Time frame: Once at end of study

    Assessed with a physician and patient questionnaire and documentation of possible confirmatory testing for changes in therapy or eligibility for interventional clinical trial screening.

  20. EBC: Therapy adherence

    Time frame: up to 60 months

    Defined as the percentage of patients in which treat-ments which are terminated as per patients' wish or because of treatment related side effect

  21. EBC: Health economics for women with breast cancer

    Time frame: up to 60 months

    EORTC QLQ C-30 (Version 3.0) (among others) and actu-al documented costs of diagnostic procedures, thera-pies, treatment of side effects and care for tumor-associated symptoms will be used to calculate health care costs, quality adjusted life years (QALY) and incre-mental cost effectiveness ratios (ICER) between patient groups.

  22. EBC: Influencing Factors of Depression in patients with breast cancer

    Time frame: Study entry and every 3 month or following a change of a therapy line(event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Depression will be assessed by patient reported ques-tionnaires e.g. CESD-R.

  23. EBC: Patient reported influencing factors on therapy adherence in patients with early breast cancer.

    Time frame: Study entry and every 3 month or following a change of a therapy line(event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Patient reported adherence for orally administered therapies will be assessed with suitable questionnaires.

  24. EBC: Incidence of adverse events, serious ad-verse events will be reported.

    Time frame: up to 60 months

    NCI Common Toxicity Criteria Version 4.03.

Other outcomes

  1. Correlation of the incidence of depression with germline gentic variation and therapies and gene expression from leukocytes.

    Time frame: Study entry and following a change of a therapy line (event-associated, e.g. after progression) up to month 60

    Depression Inventory values will be associated with blood biomarkers, single nucleotide polymorphisms and therapies.

  2. Correlation of gene alterations (mutations and or amplifications) and gene expres-sion between primary tumor and metastatic tumor for the prediction of side effects and prognosis.

    Time frame: after 60 months (after study completion)

    DNA and RNA of the primary tumor will be extracted of archival formalin fixed, paraffin embedded tumor samples and analyzed mutations, mutation changes, and differentially expressed genes. Additionally, FFPE will be used for the construction of a TMA for antibody staining.

  3. Correlation of gene alterations (mutations and or amplifications) and gene expres-sion between primary tumor, metastatic tumor and circulating tumor cells (CTCs).

    Time frame: Study entry and following a change of a therapy line (event-associated, e.g. after progression) up to month 60

    Circulating tumor cells (CTC) from selected patients will be analyzed for mutations and gene amplifications. Findings will be compared to mutations assessed from FFPE tumor material.

  4. Correlation of gene alterations (mutations and or amplifications) between primary tumor, metastatic tumor and circulating tumor DNA.

    Time frame: after 60 months (after study completion)

    Circulating DNA (ctDNA) will be analyzed for genetic variation and compared to mutations assessed from FFPE tumor material.

  5. Prediction of therapy response, prognosis and side effects with germline Single Nucleotid Polymorphisms

    Time frame: Study entry and following a change of a therapy line (event-associated, e.g. after progression) up to month 60

    Germline DNA will be used as reference for the genetic analysis of the tumor, CTCs and ctDNA. Additionally ge-nome-wide SNPs will be assessed and used for a ge-nome-wide association study.

  6. Correlation of blood protein biomarkers with side effects, and progression.

    Time frame: Study entry and following a change of a therapy line (event-associated, e.g. after progression) up to month 60.

    EGFR (1068), HSP27 (pS78), IL-1a, IL-1b, IL-2, IL-6, Il-8, PAI-1, sEGFR, ERK1/2, mTOR, TNF-a, TNF-b. P1NP, CTX, Vitamin D, PTH, OPG, RANKL, Sclerostin, DKK-1.

  7. Identification of risk factors for the development of metastatic disease in healthy women.

    Time frame: after 60 months (after study completion)

    Patients will be matched to a pool of controls, which are not part of the PRAEGNANT study, but which have been recruited during the same time.

  8. Influencing Factors of Physical Activity, Mental factors and Nutrition in patients with metastatic breast cancer

    Time frame: Study entry and every 3 month or following a change of a therapy line(event-associated, e.g. after progression) until Month 24. Every 6 months from Month 24 until Death or withdrawal of consent

    Physical activity and nutrition will be assessed with patient reported questionnaires, e.g. IPAQ and ER2.

  9. Time to progression from the beginning of subsequent therapy lines until the next progression.

    Time frame: up to 60 months

    All molecular and other measures that might predict prognosis will be associated with the-se times to progression as well.

  10. Time to death from the beginning of subsequent therapy lines

    Time frame: up to 60 months

    All molecular and other measures that might predict prognosis will be associated with these times to death as well.

Study contacts

Contact information is provided by the study sponsor or research team.

Erik Belleville, PhD

CONTACT

[email protected]

+49 931 359200 ext. 36

Sponsors and collaborators

Lead sponsor

University Hospital Tuebingen

Other

Registry information

Official study title

Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic Setting: Health Care Research, Pharmacogenomics, Biomarkers, Health Economics

Acronym: PRAEGNANT

Important dates

Study start
2014
Primary completion
2030
Study completion
2030
First posted
Jan 14, 2015
Registry last updated
Jan 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.